Table 2.
Patient characteristics
| Study | Year | Age (year) | P | Male | P | WHO PS | P | Comorbidity Score | P | Pulmonary function test | P | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Surgery | SABR | Surgery | SABR | Surgery | SABR | Surgery | SABR | Surgery | SABR | |||||||
| Crabtree et al. 12 | 2010 | 73 (mean) | 71 (mean) | NS | 59.6% | 40 & | 0.039 | — | — | — | ACE 2 (mean) | ACE 2 (mean) | NS | FEV1% (mean) 77%; DLCO% (mean) 81% | FEV1% (mean) 50%; DLCO% (mean) 50% | < 0.01/0.01 |
| Palma et al. 11 | 2011 | 79 (mean) | 79 (mean) | NS | 67% | 67% | NS | — | — | — | — | — | — | — | — | — |
| Robinson et al. 18 | 2013 | 65 (median) | 76 (median) | < 0.01 | 48.7% | 55.4% | NS | — | — | — | ACE 1 (median); CCI 3 (median) | ACE 2 (median); CCI 4 (median) | < 0.01 | FEV1% (median) 51%; DLCO% (median) 62% | FEV1% (median) 79%; DLCO% (median) 79% | < 0.01/< 0.01 |
| Varlotto et al. 17 | 2013 | ND | ND | NS | ND | ND | NS | — | — | — | ND | ND | NS | — | — | — |
| Crabtree et al. 19 | 2014 | 70 (mean) | 70.7 (mean) | NS | 57.1% | 51.8% | NS | — | — | — | ACE 2 (median) | ACE 2 (median) | NS | FEV1% (mean) 62%; DLCO% (mean) 73% | FEV1% (mean) 64%; DLCO% (mean) 55% | NS/< 0.01 |
| Mokhles et al. 21 | 2015 | 67 (mean) | 67 (mean) | NS | 60.3% | 57.5% | NS | 1 (median) | 1 (median) | NS | CCI 1 (median) | CCI 1 (median) | NS | FEV1% (mean) 80.37% | FEV1% (mean) 81.38% | NS |
| Chang et al. 15 | 2015 | 67.3 (mean) | 67.3 (mean) | NS | 41% | 45% | NS | 0 (median) | 0 (median) | NS | — | — | — | — | — | — |
| Hamaji et al. 20 | 2015 | 74 (median) | 73 (median) | NS | 78.0% | 75.6% | NS | — | — | — | CCI 1 (median) | CCI 1 (median) | NS | FEV1% (mean) 76.5% | FEV1% (mean) 70.1% | NS |
ACE, Adult Comorbidity Evaluation; CCI, Charlson Comorbidity Index; DLCO, diffusing capacity of the lung for carbon monoxide; FEV1, forced expiratory volume in 1 second; ND, no detail; NS, not significant; SABR, stereotactic ablative radiotherapy.